× Didn't find what you were looking for? Ask a question
Top Posters
Since Sunday
a
5
k
5
c
5
B
5
l
5
C
4
s
4
a
4
t
4
i
4
r
4
r
4
New Topic  
krazyrwe krazyrwe
wrote...
Posts: 466
Rep: 0 0
6 years ago
What is the most important factor contributing to the onset of pulmonary hypertension in the pa-tient with COPD?
 
  a. Alveolar hypoxia
  b. Compression of pulmonary vasculature
  c. Left ventricular failure
  d. Loss of vascular surface



Q. 2  What IV infusion has been found to improve exercise capacity, hemodynamic variables, and sur-vival in patients with severe IPAH?
 
  a. Bosentan
  b. Epoprostenol
  c. Methylprednisolone
  d. Sildenafil



Q. 3  Why is the use of oxygen to maintain oxygen saturations greater than 90 particularly important in the management of idiopathic pulmonary artery hypertension?
 
  a. These patients have a low cardiopulmo-nary reserve.
  b. Low alveolar oxygen causes vasocon-striction.
  c. Many patients have central cyanosis.
  d. These patients are especially susceptible to tissue hypoxia.



Q. 4  Why are calcium-channel blockers not used in all patients with idiopathic pulmonary artery hy-pertension?
 
  a. It causes severe side effects.
  b. Many of these patients have systemic hy-potension.
  c. Only a small percentage of IPAH patients respond.
  d. There is a high incidence of anaphylaxis.



Q. 5  In what type of IPAH patient is lung transplantation indicated?
 
  a. All pulmonary artery hypertension patients with clinically significant disease
  b. Patients not responding to vasodilators with significant cardiac dysfunction
  c. Patients with class II, class III, or class IV disease
  d. Patients with refractory hypoxemia
Read 29 times
2 Replies

Related Topics

Replies
wrote...
6 years ago
(Answer to Q. 1)  ANS: A
Alveolar hypoxia, because of its potent pulmonary vasoconstrictive effect, is probably the most important factor contributing to pulmonary hypertension in patients with COPD. Sustained alve-olar hypoxia causes pulmonary vasoconstriction and eventually medial hypertrophy, fibrosis of the intima, and narrowing of the lumen of the pulmonary blood vessels.

(Answer to Q. 2)  ANS: B
Epoprostenol delivered by continuous intravenous infusion, improves exercise capacity, hemo-dynamic variables, and survival in IPAH patients and is the treatment of choice for severely ill patients.

(Answer to Q. 3)  ANS: B
Supplemental oxygen should be used to maintain oxygen saturation greater than 90, especially because hypoxemia is a major cause of pulmonary vasoconstriction.

(Answer to Q. 4)  ANS: C
Patients with IPAH who respond to vasodilators in the short term have improved survival with long-term use of calcium-channel blockers. Thus, these agents should be considered in all patients who have significant and definite response to a short-acting vasodilator. Unfortunately, only a small fraction of IPAH patients qualify for and benefit from long-term therapy with oral calci-um-channel blockers.

(Answer to Q. 5)  ANS: B
Single or double lung transplantation has been used successfully in the treatment of patients with IPAH. Lung transplantation is indicated in the care of patients who do not respond to vasodila-tors and have significant cardiac impairment.
krazyrwe Author
wrote...
6 years ago
Smiling Face with Glasses Feeling super confident now, TY
New Topic      
Explore
Post your homework questions and get free online help from our incredible volunteers
  1218 People Browsing
 114 Signed Up Today
Related Images
  
 14
  
 20
  
 126
Your Opinion
What's your favorite funny biology word?
Votes: 328